---
- :id: 
  :uri: {}
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Subcategory of Antibodies
  :tagged:
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
    :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: CRF GL Use
    :description: CRF GL use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
    :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: SDTM Use
    :description: SDTM use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
    :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: ADaM Use
    :description: ADaM use
    :narrower: []
  :has_state: 
  :has_identifier:
    :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/ISO11179Identification#ScopedIdentifier
    :identifier: SN000116
    :version_label: ''
    :version: 1
    :semantic_version: ''
    :has_scope: 
  :origin: ''
  :change_description: ''
  :creation_date: '2016-01-01T00:00:00+00:00'
  :last_change_date: '2016-01-01T00:00:00+00:00'
  :explanatory_comment: ''
  :identifier: SN000116
  :notation: ABSCAT
  :definition: Used to define a subcategory of related antibody measurements records
    in relation to antibodies category.
  :extensible: true
  :narrower:
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: ANTI-DRUG ANTIBODIES
    :definition: Category used to retrieve information regarding antibodies that binds
      to an administered drug.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: CROSS-REACTIVITY
    :definition: Measurement of Cross-Reactivity of Anti-Drug Antibodies interacting
      with other drug or biological target.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Cross-Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: NEUTRALIZING ANTI-DRUG ANTIBODIES
    :definition: Category used to retrieve information regarding antibodies that binds
      to an administered drug and inhibits the biological activity of that drug.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Neutralizing Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  :extends: 
  :subsets: 
  :preferred_term: 
  :synonym: []
  :is_ordered: 
- :id: 
  :uri: {}
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Antibody Test Name
  :tagged:
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
    :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: CRF GL Use
    :description: CRF GL use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
    :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: SDTM Use
    :description: SDTM use
    :narrower: []
  :has_state: 
  :has_identifier:
    :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/ISO11179Identification#ScopedIdentifier
    :identifier: SN000003
    :version_label: ''
    :version: 1
    :semantic_version: ''
    :has_scope: 
  :origin: ''
  :change_description: ''
  :creation_date: '2016-01-01T00:00:00+00:00'
  :last_change_date: '2016-01-01T00:00:00+00:00'
  :explanatory_comment: ''
  :identifier: SN000003
  :notation: ABTEST
  :definition: Terminology used for antibodies test names.
  :extensible: true
  :narrower:
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: ANGAA Activity Inhibition Endpoint Titer
    :definition: The measurement of Anti-neoGAA activity Inhibition Titer Endpoint
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Activity Inhibition Endpoint Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AVE0010 Anti-Drug Antibodies
    :definition: A measurement of the AVE0010 /Lixisenatide Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: AVE0010 Anti-Drug Antibodies (Qual)
    :definition: A qualitative measurement of the AVE0010 /Lixisenatide Anti-Drug
      Antibodies in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AVE0010 Cross-Reactivity
    :definition: A measurement of the AVE0010/Lixisenatide Cross-Reactivity in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Cross-Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AVE0010 Cross-Reactivity to GLP-1
    :definition: The measurement of Cross-reactivity of Lixisenatide antibodies to
      GLP-1 in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Cross-Reactivity to GLP-1
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AVE0010 Cross-Reactivity to Glucagon
    :definition: The measurement of Cross-reactivity of Lixisenatide antibodies to
      GLucagon in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Cross-Reactivity to Glucagon
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AVE0010 Neutraliz Anti-Drug Antibodies
    :definition: The measurement of AVE0010/Lixisenatide neutralizing antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Neutralizing Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-AGlcsidase Inhibition IgE AB Status
    :definition: The measurement of Anti-alglucosidase alfa Inhibition IgE Antibody
      Status in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Inhibition IgE Antibody Status
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-AGlcsidase Uptake Inhibition Titer
    :definition: The measurement of Anti-alglucosidase alfa Uptake Inhibition Titer
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Activity Uptake Inhibition Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-AGlucosidase Activity Inhibition
    :definition: The measurement of Anti-alglucosidase alfa Inhibition Status in a
      biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Activity Inhibition
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-AGlucosidase IgG Antibody Status
    :definition: The measurement of Anti-alglucosidase alfa IgG Antibody Status in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase IgG Antibody Status
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-AGlucosidase IgG Antibody Titer
    :definition: The measurement of Anti-alglucosidase alfa IgG Antibody Titer in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase IgG Antibody Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-AGlucosidase Inhibition IgE AB
    :definition: The measurement of Anti-alglucosidase alfa Inhibition IgE Antibody
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Inhibition IgE Antibody
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-Alpha Glucosidase Inhibition Titer
    :definition: The measurement of Anti-alglucosidase alfa Inhibition Titer in a
      biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Inhibition Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-Alpha Glucosidase Inhibition Uptake
    :definition: The measurement of Anti-alglucosidase alfa Inhibition Uptake in a
      biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Inhibition Uptake
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-NeoGAA Activity Inhibition
    :definition: The measurement of Anti-neoGAA activity Inhibition Status in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Activity Inhibition
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-NeoGAA Activity Uptake Inhibition
    :definition: The measurement of Anti-neoGAA activity Uptake Inhibition Status
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Activity Uptake Inhibition
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-NeoGAA Antibody
    :definition: The measurement of anti-neoGAA antibody status in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Antibody
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-NeoGAA Antibody Titer
    :definition: The measurement of Anti-neoGAA antibody titer in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Antibody Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-NeoGAA IgE Antibody
    :definition: The measurement of Anti-neoGAA IgE Antibody in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA IgE Antibody
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-NeoGAA IgE Antibody Status
    :definition: The measurement of Anti-neoGAA IgE Antibody Status in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA IgE Antibody Status
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Anti-NeoGAA Uptake Inhibition Titer
    :definition: The measurement of Anti-neoGAA activity Uptake Inhibition Titer in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Uptake Inhibition Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: GLP-1 Neutraliz Anti-Drug Antibodies
    :definition: The measurement of GLP-1 neutralizing anti-drug antibodies in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: GLP-1 Neutralizing Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Glucagon Cross Reactivity
    :definition: A measurement of the Glucagon Cross-Reactivity in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Glucagon Cross Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: Glucagon Neutraliz Anti-Drug Antibodies
    :definition: The measurement of Glucagon neutralizing antibodies in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Glucagon Neutralizing Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: HOE901 Anti-Drug Antibodies
    :definition: A measurement of the HOE901/insulin glargine anti-drug antibodies
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: HOE901 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: HOE901 Anti-Drug Antibodies (Qual)
    :definition: A qualitative measurement of the HOE901/insulin glargine anti-drug
      antibody in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: HOE901 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: HOE901 Cross-Reactivity
    :definition: The measurement of the cross-reactivity of HOE901/insulin glargine
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: HOE901 Cross-Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR156597 Anti-Drug Antibodies
    :definition: A measurement of the SAR156597 anti-drug antibody in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR156597 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: SAR156597 Anti-Drug Antibodies (Qual)
    :definition: A qualitative measurement of the SAR156597 anti-drug antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR156597 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR156597 Neutraliz Anti-Drug Antibodies
    :definition: A measurement of the SAR156597 neutralizing Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR156597 Neutralizing Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: SAR231893 Anti-Drug Antibodies (Qual)
    :definition: A qualitative measurement of the SAR231893 Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR231893 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR231893 Presence of Nabs
    :definition: A measurement of the SAR231893 neutralizing Anti-Drug Antibodies
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR231893 Presence of Nabs
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR236553 Anti-Drug Antibodies
    :definition: A measurement of the SAR236553 Anti-Drug Antibody in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR236553 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR236553 Neutraliz Anti-Drug Antibodies
    :definition: A measurement of the SAR236553 neutralizing Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR236553 Neutralizing Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: SAR341402 Anti-Drug Antibodies (Qual)
    :definition: The qualitative measurement of Aspart antibody in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR341402 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR341402 Antibodies Titer
    :definition: The measurement of Aspart antibodies as a titer in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR341402 Antibodies Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR341402 Cross-Reactivity
    :definition: The cross reactivity measurement of Aspart antibodies to human insulin
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR341402 Cross-Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: SAR425899 Anti-Drug Antibodies (Qual)
    :definition: A qualitative measurement of the SAR425899 Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR425899 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR425899 Anti-Drug Antibodies Titer
    :definition: A titration of the SAR425899 Anti-Drug Antibodies Titer in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR425899 Anti-Drug Antibodies Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR425899 Cross-Reactivity
    :definition: A measurement of the SAR425899 Cross-Reactivity in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR425899 Cross-Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR425899 Neutraliz Anti-Drug Antibodies
    :definition: A measurement of the SAR425899 Neutralizing Antibodies in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR425899 Neutralizing Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR428926 Anti-Drug Antibodies
    :definition: A measurement of the SAR428926/Maytansin Loaded Anti-Lamp1 Anti-Drug
      Antibodies in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR428926 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: SAR428926 Anti-Drug Antibodies (Qual)
    :definition: A qualitative measurement of the SAR428926/Maytansin Loaded Anti-Lamp1
      Anti-Drug Antibodies in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR428926 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: SAR439459 Anti-Drug Antibodies (Qual)
    :definition: A qualitative measurement of the SAR439459 Anti-Drug Antibodies in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR439459 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR439459 Anti-Drug Antibodies Titer
    :definition: A titration of the SAR439459 Anti-Drug Antibodies Titer in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR439459 Anti-Drug Antibodies Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: SAR650984 Anti-Drug Antibodies
    :definition: A measurement of the SAR650984 Anti-Drug Antibodies in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR650984 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: SAR650984 Anti-Drug Antibodies (Qual)
    :definition: A qualitative measurement of the SAR650984 Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR650984 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  :extends: 
  :subsets: 
  :preferred_term: 
  :synonym: []
  :is_ordered: 
- :id: 
  :uri: {}
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Antibody Test Code
  :tagged:
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
    :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: CRF GL Use
    :description: CRF GL use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
    :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: SDTM Use
    :description: SDTM use
    :narrower: []
  :has_state: 
  :has_identifier:
    :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/ISO11179Identification#ScopedIdentifier
    :identifier: SN000004
    :version_label: ''
    :version: 1
    :semantic_version: ''
    :has_scope: 
  :origin: ''
  :change_description: ''
  :creation_date: '2016-01-01T00:00:00+00:00'
  :last_change_date: '2016-01-01T00:00:00+00:00'
  :explanatory_comment: ''
  :identifier: SN000004
  :notation: ABTESTCD
  :definition: Terminology used for antibodies test codes.
  :extensible: true
  :narrower:
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: A0010AB
    :definition: A measurement of the AVE0010 /Lixisenatide Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: A0010ABQ
    :definition: A qualitative measurement of the AVE0010 /Lixisenatide Anti-Drug
      Antibodies in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: A0010C
    :definition: A measurement of the AVE0010/Lixisenatide Cross-Reactivity in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Cross-Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: A0010NAB
    :definition: The measurement of AVE0010/Lixisenatide neutralizing antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Neutralizing Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: A010GCGC
    :definition: The measurement of Cross-reactivity of Lixisenatide antibodies to
      GLucagon in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Cross-Reactivity to Glucagon
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: A010GP1C
    :definition: The measurement of Cross-reactivity of Lixisenatide antibodies to
      GLP-1 in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: AVE0010 Cross-Reactivity to GLP-1
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AAGAUIT
    :definition: The measurement of Anti-alglucosidase alfa Uptake Inhibition Titer
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Activity Uptake Inhibition Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AAGIEABS
    :definition: The measurement of Anti-alglucosidase alfa Inhibition IgE Antibody
      Status in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Inhibition IgE Antibody Status
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AAGIGEAB
    :definition: The measurement of Anti-alglucosidase alfa Inhibition IgE Antibody
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Inhibition IgE Antibody
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AAGIGGAS
    :definition: The measurement of Anti-alglucosidase alfa IgG Antibody Status in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase IgG Antibody Status
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AAGIGGAT
    :definition: The measurement of Anti-alglucosidase alfa IgG Antibody Titer in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase IgG Antibody Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AAGLCAI
    :definition: The measurement of Anti-alglucosidase alfa Inhibition Status in a
      biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Activity Inhibition
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AAGLCIT
    :definition: The measurement of Anti-alglucosidase alfa Inhibition Titer in a
      biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Inhibition Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: AAGLCUI
    :definition: The measurement of Anti-alglucosidase alfa Inhibition Uptake in a
      biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-Alpha Glucosidase Inhibition Uptake
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: ANGAAAB
    :definition: The measurement of anti-neoGAA antibody status in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Antibody
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: ANGAAABT
    :definition: The measurement of Anti-neoGAA antibody titer in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Antibody Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: ANGAAAI
    :definition: The measurement of Anti-neoGAA activity Inhibition Status in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Activity Inhibition
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: ANGAAAUI
    :definition: The measurement of Anti-neoGAA activity Uptake Inhibition Status
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Activity Uptake Inhibition
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: ANGAAEAB
    :definition: The measurement of Anti-neoGAA IgE Antibody in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA IgE Antibody
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: ANGAAEAS
    :definition: The measurement of Anti-neoGAA IgE Antibody Status in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA IgE Antibody Status
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: ANGAAIET
    :definition: The measurement of Anti-neoGAA activity Inhibition Titer Endpoint
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Activity Inhibition Endpoint Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: ANGAAUIT
    :definition: The measurement of Anti-neoGAA activity Uptake Inhibition Titer in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Anti-NeoGAA Uptake Inhibition Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: GCGC
    :definition: A measurement of the Glucagon Cross-Reactivity in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Glucagon Cross Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: GCGNAB
    :definition: The measurement of Glucagon neutralizing antibodies in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Glucagon Neutralizing Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: GLP1NAB
    :definition: The measurement of GLP-1 neutralizing anti-drug antibodies in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: GLP-1 Neutraliz Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: HE901AB
    :definition: A measurement of the HOE901/insulin glargine anti-drug antibodies
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: HOE901 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: HE901ABQ
    :definition: A qualitative measurement of the HOE901/insulin glargine anti-drug
      antibody in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: HOE901 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: HE901C
    :definition: The measurement of the cross-reactivity of HOE901/insulin glargine
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: HOE901 Cross-Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S0984AB
    :definition: A measurement of the SAR650984 Anti-Drug Antibodies in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR650984 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: S0984ABQ
    :definition: A qualitative measurement of the SAR650984 Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR650984 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: S1402ABQ
    :definition: The qualitative measurement of Aspart antibody in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR341402 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S1402ABT
    :definition: The measurement of Aspart antibodies as a titer in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR341402 Antibodies Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S1402C
    :definition: The cross reactivity measurement of Aspart antibodies to human insulin
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR341402 Cross-Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: S1893ABQ
    :definition: A qualitative measurement of the SAR231893 Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR231893 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: S5899ABQ
    :definition: A qualitative measurement of the SAR425899 Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR425899 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S5899ABT
    :definition: A titration of the SAR425899 Anti-Drug Antibodies Titer in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR425899 Anti-Drug Antibodies Titer
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S5899C
    :definition: A measurement of the SAR425899 Cross-Reactivity in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR425899 Cross-Reactivity
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S5899NAB
    :definition: A measurement of the SAR425899 Neutralizing Antibodies in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR425899 Neutralizing Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S6553AB
    :definition: A measurement of the SAR236553 Anti-Drug Antibody in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR236553 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S6553NAB
    :definition: A measurement of the SAR236553 neutralizing Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR236553 Neutralizing Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S6597AB
    :definition: A measurement of the SAR156597 anti-drug antibody in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR156597 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: S6597ABQ
    :definition: A qualitative measurement of the SAR156597 anti-drug antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR156597 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S6597NAB
    :definition: A measurement of the SAR156597 neutralizing Anti-Drug Antibody in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR156597 Neutralizing Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S8926AB
    :definition: A measurement of the SAR428926/Maytansin Loaded Anti-Lamp1 Anti-Drug
      Antibodies in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR428926 Anti-Drug Antibodies
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: S8926ABQ
    :definition: A qualitative measurement of the SAR428926/Maytansin Loaded Anti-Lamp1
      Anti-Drug Antibodies in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR428926 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S893NABS
    :definition: A measurement of the SAR231893 neutralizing Anti-Drug Antibodies
      in a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR231893 Presence of Nabs
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: S9459ABQ
    :definition: A qualitative measurement of the SAR439459 Anti-Drug Antibodies in
      a biological specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR439459 Anti-Drug Antibodies (Qual)
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    :identifier: ''
    :notation: S9459ABT
    :definition: A titration of the SAR439459 Anti-Drug Antibodies Titer in a biological
      specimen.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: SAR439459 Anti-Drug Antibodies Titer
      :tagged: []
    :synonym: []
  :extends: 
  :subsets: 
  :preferred_term: 
  :synonym: []
  :is_ordered: 
- :id: 
  :uri: {}
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change
    Questionnaire Test Code
  :tagged:
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
    :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: CRF GL Use
    :description: CRF GL use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
    :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: SDTM Use
    :description: SDTM use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
    :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: ADaM Use
    :description: ADaM use
    :narrower: []
  :has_state: 
  :has_identifier:
    :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/ISO11179Identification#ScopedIdentifier
    :identifier: C103459
    :version_label: ''
    :version: 1
    :semantic_version: ''
    :has_scope: 
  :origin: ''
  :change_description: ''
  :creation_date: '2016-01-01T00:00:00+00:00'
  :last_change_date: '2016-01-01T00:00:00+00:00'
  :explanatory_comment: ''
  :identifier: C103459
  :notation: ACGC01TC
  :definition: Alzheimer's Disease Cooperative Study-Clinical Global Impression of
    Change test code.
  :extensible: false
  :narrower:
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: ACGC0101
    :definition: Alzheimer's Disease Cooperative Study-Clinical Global Impression
      of Change - Clinical impression of change from baseline.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: ACGC01-Clinical Impression of Change
      :tagged: []
    :synonym:
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: ACGC01-Clinical Impression of Change
      :tagged: []
  :extends: 
  :subsets: 
  :preferred_term: 
  :synonym: []
  :is_ordered: 
- :id: 
  :uri: {}
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Alzheimer's Disease Cooperative Study-Clinical Global Impression of Change
    Questionnaire Test Name
  :tagged:
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
    :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: CRF GL Use
    :description: CRF GL use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
    :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: SDTM Use
    :description: SDTM use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
    :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: ADaM Use
    :description: ADaM use
    :narrower: []
  :has_state: 
  :has_identifier:
    :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/ISO11179Identification#ScopedIdentifier
    :identifier: C103458
    :version_label: ''
    :version: 1
    :semantic_version: ''
    :has_scope: 
  :origin: ''
  :change_description: ''
  :creation_date: '2016-01-01T00:00:00+00:00'
  :last_change_date: '2016-01-01T00:00:00+00:00'
  :explanatory_comment: ''
  :identifier: C103458
  :notation: ACGC01TN
  :definition: Alzheimer's Disease Cooperative Study-Clinical Global Impression of
    Change test name.
  :extensible: false
  :narrower:
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: ACGC01-Clinical Impression of Change
    :definition: Alzheimer's Disease Cooperative Study-Clinical Global Impression
      of Change - Clinical impression of change from baseline.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: ACGC01-Clinical Impression of Change
      :tagged: []
    :synonym:
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: ACGC01-Clinical Impression of Change
      :tagged: []
  :extends: 
  :subsets: 
  :preferred_term: 
  :synonym: []
  :is_ordered: 
- :id: 
  :uri: {}
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Action Taken with Study Treatment Subset 03
  :tagged:
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
    :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: CRF GL Use
    :description: CRF GL use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
    :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: SDTM Use
    :description: SDTM use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
    :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: ADaM Use
    :description: ADaM use
    :narrower: []
  :has_state: 
  :has_identifier:
    :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/ISO11179Identification#ScopedIdentifier
    :identifier: C66767
    :version_label: ''
    :version: 1
    :semantic_version: ''
    :has_scope: 
  :origin: ''
  :change_description: ''
  :creation_date: '2016-01-01T00:00:00+00:00'
  :last_change_date: '2016-01-01T00:00:00+00:00'
  :explanatory_comment: ''
  :identifier: C66767
  :notation: ACN_03
  :definition: Terminology specifying changes to the study treatment as a result of
    an adverse event.
  :extensible: false
  :narrower:
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DOSE INCREASED
    :definition: An indication that a medication schedule was modified by addition;
      either by changing the frequency, strength or amount. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Increased
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DOSE NOT CHANGED
    :definition: An indication that a medication schedule was maintained. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Not Changed
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DOSE REDUCED
    :definition: An indication that a medication schedule was modified by subtraction,
      either by changing the frequency, strength or amount. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Reduced
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DRUG INTERRUPTED
    :definition: An indication that a medication schedule was modified by temporarily
      terminating a prescribed regimen of medication. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Drug Interrupted
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DRUG WITHDRAWN
    :definition: An indication that a medication schedule was modified through termination
      of a prescribed regimen of medication. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Drug Withdrawn
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: MULTIPLE
    :definition: More than one. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: MULTIPLE
      :tagged: []
    :synonym:
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: Many
      :tagged: []
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: Several
      :tagged: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: NOT APPLICABLE
    :definition: Determination of a value is not relevant in the current context.
      (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Not Applicable
      :tagged: []
    :synonym:
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: NA
      :tagged: []
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: Not Applicable
      :tagged: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: UNKNOWN
    :definition: Not known, not observed, not recorded, or refused. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Unknown
      :tagged: []
    :synonym:
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: U
      :tagged: []
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: Unknown
      :tagged: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: DOSE INCREASED
    :definition: An indication that a medication schedule was modified by addition;
      either by changing the frequency, strength or amount. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Increased
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: DOSE NOT CHANGED
    :definition: An indication that a medication schedule was maintained. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Not Changed
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: DOSE REDUCED
    :definition: An indication that a medication schedule was modified by subtraction,
      either by changing the frequency, strength or amount. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Reduced
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: DRUG INTERRUPTED
    :definition: An indication that a medication schedule was modified by temporarily
      terminating a prescribed regimen of medication. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Drug Interrupted
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: DRUG WITHDRAWN
    :definition: An indication that a medication schedule was modified through termination
      of a prescribed regimen of medication. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Drug Withdrawn
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: NOT APPLICABLE
    :definition: Determination of a value is not relevant in the current context.
      (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Not Applicable
      :tagged: []
    :synonym:
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: NA
      :tagged: []
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: Not Applicable
      :tagged: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: DRUG WITHDRAWN
    :definition: An indication that a medication schedule was modified through termination
      of a prescribed regimen of medication. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Drug Withdrawn
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    :identifier: ''
    :notation: NOT APPLICABLE
    :definition: Determination of a value is not relevant in the current context.
      (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Not Applicable
      :tagged: []
    :synonym:
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: NA
      :tagged: []
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: Not Applicable
      :tagged: []
  :extends: 
  :subsets: 
  :preferred_term: 
  :synonym: []
  :is_ordered: 
- :id: 
  :uri: {}
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Action Taken with Study Treatment Collected
  :tagged:
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
    :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: CRF GL Use
    :description: CRF GL use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
    :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: SDTM Use
    :description: SDTM use
    :narrower: []
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
    :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: ADaM Use
    :description: ADaM use
    :narrower: []
  :has_state: 
  :has_identifier:
    :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/ISO11179Identification#ScopedIdentifier
    :identifier: SN000730
    :version_label: ''
    :version: 1
    :semantic_version: ''
    :has_scope: 
  :origin: ''
  :change_description: ''
  :creation_date: '2016-01-01T00:00:00+00:00'
  :last_change_date: '2016-01-01T00:00:00+00:00'
  :explanatory_comment: ''
  :identifier: SN000730
  :notation: ACNC
  :definition: Terminology specifying changes to the study treatment as a result of
    an adverse event as collected on the case report form.
  :extensible: false
  :narrower:
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DOSE DELAYED
    :definition: An indication that a medication schedule was postponed.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Delayed
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DOSE DELAYED AND REDUCED
    :definition: An indication that a medication schedule was postponed and modified
      by subtraction by strength or amount.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Delayed and Reduced
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DOSE INCREASED
    :definition: An indication that a medication schedule was modified by addition;
      either by changing the frequency, strength or amount. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Increased
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DOSE NOT CHANGED
    :definition: An indication that a medication schedule was maintained. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Not Changed
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DOSE REDUCED
    :definition: An indication that a medication schedule was modified by subtraction,
      either by changing the frequency, strength or amount. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Reduced
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DRUG WITHDRAWN
    :definition: An indication that a medication schedule was modified through termination
      of a prescribed regimen of medication. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Drug Withdrawn
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: NOT APPLICABLE
    :definition: Determination of a value is not relevant in the current context.
      (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Not Applicable
      :tagged: []
    :synonym:
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: NA
      :tagged: []
    - :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#Synonym
      :label: Not Applicable
      :tagged: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2QzODAxY2JiLTQ1YTEtNDk3OC04ZjBjLWEyNjQ3N2Y3MTk5Mg==
      :uri: http://www.assero.co.uk/CSN#d3801cbb-45a1-4978-8f0c-a26477f71992
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: CRF GL Use
      :description: CRF GL use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2ZhNmU5YTQ4LWM2Y2QtNGY2Ny04NTAxLWJjODg5MjljMWM3ZQ==
      :uri: http://www.assero.co.uk/CSN#fa6e9a48-c6cd-4f67-8501-bc88929c1c7e
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: SDTM Use
      :description: SDTM use
      :narrower: []
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: DRUG INTERRUPTED
    :definition: An indication that a medication schedule was modified by temporarily
      terminating a prescribed regimen of medication. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Drug Interrupted
      :tagged: []
    :synonym: []
  :extends: 
  :subsets: 
  :preferred_term: 
  :synonym: []
  :is_ordered: 
- :id: 
  :uri: {}
  :rdf_type: http://www.assero.co.uk/Thesaurus#ManagedConcept
  :label: Action Taken with Study Treatment Numeric
  :tagged:
  - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
    :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
    :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
    :pref_label: ADaM Use
    :description: ADaM use
    :narrower: []
  :has_state: 
  :has_identifier:
    :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/ISO11179Identification#ScopedIdentifier
    :identifier: SN000005
    :version_label: ''
    :version: 1
    :semantic_version: ''
    :has_scope: 
  :origin: ''
  :change_description: ''
  :creation_date: '2016-01-01T00:00:00+00:00'
  :last_change_date: '2016-01-01T00:00:00+00:00'
  :explanatory_comment: ''
  :identifier: SN000005
  :notation: ACNN
  :definition: Numeric - Terminology specifying changes to the study treatment as
    a result of an adverse event.
  :extensible: false
  :narrower:
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: '1'
    :definition: A numeric, one, indication that a medication schedule was maintained.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Not Changed
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: '10'
    :definition: A numeric value, ten, that indicate determination of a value is not
      relevant in the current context.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Not Applicable
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: '2'
    :definition: A numeric, two, indication that a medication schedule was modified
      by subtraction, either by changing the frequency, strength or amount.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Reduced
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: '3'
    :definition: A numeric,three, indication that a medication schedule was modified
      by temporarily terminating a prescribed regimen of medication.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Drug Interrupted
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: '4'
    :definition: A numeric, four, indication that a medication schedule was modified
      through termination of a prescribed regimen of medication.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Drug Withdrawn
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: '5'
    :definition: A numeric, five, indication that a medication schedule was modified
      by addition; either by changing the frequency, strength or amount.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Increased
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: '6'
    :definition: A numeric indication, six, that a medication schedule was postponed.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Delayed
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: '7'
    :definition: A numeric value, seven, that gives an indication that a medication
      schedule was postponed and modified by subtraction by strength or amount.
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Dose Delayed and Reduced
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: '8'
    :definition: A numeric, eight, that indicate more than one. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Multiple
      :tagged: []
    :synonym: []
  - :id: 
    :uri: {}
    :rdf_type: http://www.assero.co.uk/Thesaurus#UnmanagedConcept
    :label: ''
    :tagged:
    - :id: aHR0cDovL3d3dy5hc3Nlcm8uY28udWsvQ1NOI2IwMzRhZjhmLWVhNDMtNDg4MS1iZTRjLWRiZGY1MmY4NTc3MQ==
      :uri: http://www.assero.co.uk/CSN#b034af8f-ea43-4881-be4c-dbdf52f85771
      :rdf_type: http://www.assero.co.uk/ISO11179Concepts#ConceptSystemNode
      :pref_label: ADaM Use
      :description: ADaM use
      :narrower: []
    :identifier: ''
    :notation: '9'
    :definition: A numeric value, nine, that indicate not known, not observed, not
      recorded, or refused. (NCI)
    :extensible: false
    :narrower: []
    :preferred_term:
      :id: 
      :uri: {}
      :rdf_type: http://www.assero.co.uk/Thesaurus#PreferredTerm
      :label: Unknown
      :tagged: []
    :synonym: []
  :extends: 
  :subsets: 
  :preferred_term: 
  :synonym: []
  :is_ordered: 
